See more : The Daito Bank, Ltd. (8563.T) Income Statement Analysis – Financial Results
Complete financial analysis of Aadi Bioscience, Inc. (AADI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aadi Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- iStreet Network Limited (ISTRNETWK.BO) Income Statement Analysis – Financial Results
- Lion One Metals Limited (LOMLF) Income Statement Analysis – Financial Results
- LithiumBank Resources Corp. (LBNKF) Income Statement Analysis – Financial Results
- Kaori Heat Treatment Co., Ltd. (8996.TW) Income Statement Analysis – Financial Results
- BKW AG (BKW.SW) Income Statement Analysis – Financial Results
Aadi Bioscience, Inc. (AADI)
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.35M | 15.22M | 1.00M | 14.00M | 749.00K | 20.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.81M | 1.34M | 276.00K | 176.00K | 76.50K | 0.00 | 51.27K | 69.67K | 57.98K | 23.97K | 22.82K | 22.39K | 23.59K | 20.51K | 0.00 | 0.00 |
| Gross Profit | 21.55M | 13.88M | 724.00K | 13.82M | 672.50K | 20.16M | -51.27K | -69.67K | -57.98K | -23.97K | -22.82K | -22.39K | -23.59K | -20.51K | 0.00 | 0.00 |
| Gross Profit Ratio | 88.47% | 91.23% | 72.40% | 98.74% | 89.79% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.93M | 32.66M | 19.67M | 15.01M | 12.82M | 17.85M | 12.15M | 11.37M | 11.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 18.51M | 2.12M | 1.85M | 13.49M | 9.24M | 29.49K | 23.01K | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 7.83M | -46.69K | -51.27K | 5.17M | 5.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 44.55M | 40.18M | 18.51M | 2.12M | 9.68M | 13.44M | 9.19M | 5.20M | 5.80M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.06M | -120.00K | -580.00K | -142.73K | -6.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.62K |
| Operating Expenses | 93.48M | 72.84M | 38.06M | 16.55M | 22.50M | 31.29M | 21.34M | 16.56M | 17.43M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | -33.62K |
| Cost & Expenses | 96.29M | 74.17M | 38.06M | 16.55M | 22.58M | 31.34M | 21.39M | 16.63M | 17.49M | 22.82K | 22.39K | 23.59K | 20.51K | 41.02K | 0.00 | -33.62K |
| Interest Income | 6.40M | 2.40M | 13.00K | 41.00K | 1.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 231.00K | 230.00K | 665.00K | 815.00K | 0.00 | 778.22K | -105.78K | 9.94K | 8.43K | 5.88K | 4.97K | 3.60K | 1.89K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 169.00K | 159.00K | 276.00K | 176.00K | 76.50K | 46.69K | 51.27K | 69.67K | 57.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -65.37M | -60.12M | -109.15M | -2.49M | -24.44M | -10.35M | -21.24M | -16.43M | -17.01M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
| EBITDA Ratio | -268.40% | -371.71% | -3,546.30% | -18.94% | -3,004.55% | -55.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.93M | -58.96M | -111.22M | -2.55M | -22.58M | -11.18M | -21.39M | -16.63M | -17.49M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
| Operating Income Ratio | -295.36% | -387.47% | -11,121.70% | -18.21% | -3,014.77% | -55.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.17M | 2.17M | 1.13M | -927.00K | 1.17M | 784.61K | -12.07K | -349.93K | 416.33K | 17.15K | 16.95K | 17.42K | 19.99K | 18.62K | 0.00 | 0.00 |
| Income Before Tax | -65.77M | -60.51M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
| Income Before Tax Ratio | -270.04% | -397.69% | -11,008.80% | -24.83% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.50M | 2.00K | 2.00K | 1.30K | 778.22K | -12.06K | -3.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -65.77M | -57.01M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
| Net Income Ratio | -270.04% | -374.67% | -11,009.00% | -24.84% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
Aadi Bioscience, Inc. (AADI) Q2 2023 Earnings Call Transcript
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Scott Giacobello - Interim CEO, President, and CFO Loretta Itri - Chief Medical...
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates
Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.73 per share a year ago.
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update
Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to include programs in Endometrial Cancer and Neuroendocrine...
Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update
Company to Host Conference Call and Webcast on Wednesday, August 9, 2023 LOS ANGELES , Aug. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations...
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Aadi Bioscience: High Risk/High Reward
Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is approved for one rare indication and is being evaluated for additional tumor types....
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting
LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters...
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023
LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three...
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Tops Revenue Estimates
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 20% and 14.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience: Commercial Stage With Large Market In Label Expansion
AADI is a commercial stage company with a potential label expansion ahead. It is adequately funded, run by expert management, and has a major catalyst next year.
Source: https://incomestatements.info
Category: Stock Reports